Crescita Therapeutics Gross Profit vs. Price To Earning
| CRRTF Stock | USD 0.45 0.00 0.00% |
For Crescita Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Crescita Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Crescita Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Crescita Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Crescita Therapeutics over time as well as its relative position and ranking within its peers.
Crescita |
Crescita Therapeutics Price To Earning vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Crescita Therapeutics's current stock value. Our valuation model uses many indicators to compare Crescita Therapeutics value to that of its competitors to determine the firm's financial worth. Crescita Therapeutics is number one stock in gross profit category among its peers. It also is number one stock in price to earning category among its peers . The ratio of Gross Profit to Price To Earning for Crescita Therapeutics is about 20,437 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Crescita Therapeutics' earnings, one of the primary drivers of an investment's value.Crescita Price To Earning vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Crescita Therapeutics |
| = | 10.01 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Crescita Therapeutics |
| = | 490.00 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Crescita Price To Earning Comparison
Crescita Therapeutics is currently under evaluation in price to earning category among its peers.
Crescita Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Crescita Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Crescita Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Crescita Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Crescita Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. Crescita Therapeutics is traded on OTC Exchange in the United States.
Crescita Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Crescita Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Crescita Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Crescita Therapeutics' important profitability drivers and their relationship over time.
Use Crescita Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crescita Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crescita Therapeutics will appreciate offsetting losses from the drop in the long position's value.Crescita Therapeutics Pair Trading
Crescita Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Crescita Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crescita Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crescita Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crescita Therapeutics to buy it.
The correlation of Crescita Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crescita Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crescita Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crescita Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Crescita Therapeutics position
In addition to having Crescita Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Crescita Pink Sheet
To fully project Crescita Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Crescita Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Crescita Therapeutics' income statement, its balance sheet, and the statement of cash flows.